Alignment Healthcare, Inc. SEC Filings

Joseph S. Konowiecki, a director of Alignment Healthcare, Inc. (ALHC), reported a non-discretionary sale of 16,076 shares of common stock on 09/16/2025 at a price of $16.24 per share. The sale represents shares withheld to satisfy tax withholding obligations tied to the vesting of restricted stock units and is explicitly described as not a discretionary trade. After the transaction, the reporting person beneficially owned 1,110,973 shares, held directly. The filing discloses routine insider tax-related share withholding rather than an open-market decision to reduce ownership.

General Atlantic (ALN HLTH), L.P. reported an open-market sale of 13,460,000 shares of Alignment Healthcare, Inc. (ALHC) that settled on 09/12/2025 at a net price of $16.01 per share. Following the transaction, GA ALN directly held 30,533,323 shares. The filing reports 30,842,175 shares beneficially owned in total on an indirect basis, which reflects additional shares and restricted stock units held by two individuals for the benefit of General Atlantic Service Company, L.P. The reporting entity is listed as both a director and a 10% owner. The form is signed by Michael Gosk on 09/16/2025.

General Atlantic reported an open-market sale of 13,460,000 shares of Alignment Healthcare (ALHC) common stock settled on 09/12/2025 at a net price of $16.01 per share. After the transaction, General Atlantic (GA ALN) held 30,533,323 shares directly and, when combined with certain shares and restricted stock units held for the benefit of General Atlantic Service Company, L.P., the reporting group is shown as beneficially owning 30,842,175 shares in the filing. The Form 4 identifies multiple related General Atlantic entities and states they may be deemed a group while disclaiming broader beneficial ownership. The filing is signed by Michael Gosk on 09/16/2025 and lists the reporting persons as directors-by-deputization for Section 16 purposes.

Alignment Healthcare, Inc. (ALHC) filed a Form 144 notifying the proposed sale of 13,460,000 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $215,494,600.00. The filing lists the approximate sale date as 09/10/2025 and shows 198,031,417 shares outstanding, implying the proposed sale represents roughly 6.8% of outstanding shares. The securities were acquired on 09/16/2016 in a corporate reorganization involving Alignment Healthcare, Inc., and payment/consideration details reference remarks. No securities sales by the person in the past three months were reported.

Alignment Healthcare insider Christopher J. Joyce, the companys Chief Legal and Administrative Officer and a director, reported two non-discretionary sales of common stock on 09/10/2025 to satisfy tax withholding for vested restricted stock units. Mr. Joyce sold 22,128 shares at a weighted-average price of $16.2293 (per-share trades ranged $15.74$16.735) and 8,811 shares at a weighted-average price of $16.8555 (per-share trades ranged $16.74$17.24). After these transactions he beneficially owns 352,403 and 343,592 shares as reported on each line, respectively. The filer certified the sales were to cover tax withholding and not discretionary trades.

Robert L. Scavo, Chief Information Officer and director of Alignment Healthcare, Inc. (ALHC), sold shares on 09/10/2025 to satisfy tax withholding from RSU vesting. The filing reports two non-discretionary sales: 21,123 shares at a weighted-average price of $16.2293 (individual trade prices ranged $15.74 to $16.735) and 8,412 shares at a weighted-average price of $16.8555 (individual trade prices ranged $16.74 to $17.24). After these transactions he beneficially owned 580,967 shares following the first set and 572,555 shares following the second set, held directly. The sales were executed pursuant to tax-withholding obligations and were not discretionary trades.

Alignment Healthcare insider sale under 10b5-1 plan; sales were tax-withholding for vested RSUs. On 09/10/2025 Dawn C. Maroney reported three non-discretionary sales of Alignment Healthcare (ALHC) common stock. The reported transactions were: sale of 77,555 shares at a weighted-average price of $16.2293 (per-share sales ranged $15.74–$16.735), sale of 30,884 shares at a weighted-average price of $16.8555 (range $16.74–$17.24), and sales totaling 107,223 shares under a Rule 10b5-1 plan adopted 05/22/2025 at a weighted-average price of $16.4163 (range $16.03–$16.73). Following these transactions the reporting person beneficially owned 1,797,237 shares.

Joseph S. Konowiecki, a director of Alignment Healthcare, Inc. (ALHC), reported a sale of 25,000 shares of the company's common stock on 09/09/2025 at a price of $17 per share. After the reported transaction he beneficially owned 1,127,049 shares, held directly. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on 03/05/2025, and the Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure is limited to this single non-derivative sale and ownership snapshot; no options, acquisitions, or other transactions are reported.

John E. Kao, Alignment Healthcare (ALHC) Chief Executive Officer and Director, reported multiple stock sales on 09/10/2025. The Form 4 shows three non-derivative disposition entries: 253,908 shares sold at a weighted-average price of $16.2293 (per-share range $15.74–$16.735), 101,110 shares sold at a weighted-average price of $16.8555 (per-share range $16.74–$17.24), and 180,000 shares sold under a Rule 10b5-1 plan at a weighted-average price of $16.4164 (per-share range $16.03–$16.73). The first two sales were to cover tax withholding on vested restricted stock units and are described as non-discretionary; the 180,000-share sale was executed under a pre-established 10b5-1 plan adopted 03/12/2025. Following the reported transactions, the filing indicates beneficial ownership figures of 4,634,678 shares, 4,533,568 shares, and an indirect holding of 1,193,100 shares through the JEK Trust (dated February 8, 2021) for which Mr. Kao is trustee.